CIBC Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26M Sell
41,660
-857
-2% -$583K 0.06% 226
2026
Q1
$32.9M Sell
42,517
-150
-0.4% -$115K 0.08% 179
2025
Q4
$32.9M Buy
42,667
+10,329
+32% +$7.01M 0.08% 175
2025
Q3
$18.2M Sell
32,338
-585
-2% -$331K 0.05% 222
2025
Q2
$17.3M Sell
32,923
-1,573
-5% -$878K 0.05% 224
2025
Q1
$21.9M Buy
34,496
+110
+0.3% +$75.7K 0.07% 183
2024
Q4
$24.5M Buy
34,386
+1,034
+3% +$868K 0.08% 163
2024
Q3
$35.1M Buy
33,352
+1,843
+6% +$2.05M 0.11% 128
2024
Q2
$33.1M Buy
31,509
+4
+0% +$3.88K 0.12% 123
2024
Q1
$30.3M Buy
31,505
+1,692
+6% +$1.61M 0.11% 133
2023
Q4
$26.2M Buy
29,813
+142
+0.5% +$117K 0.1% 145
2023
Q3
$24.4M Buy
29,671
+2,809
+10% +$2.21M 0.1% 139
2023
Q2
$19.3M Sell
26,862
-148
-0.5% -$114K 0.07% 166
2023
Q1
$22.2M Buy
27,010
+336
+1% +$253K 0.09% 152
2022
Q4
$19.2M Sell
26,674
-11
-0% -$8.12K 0.08% 155
2022
Q3
$18.4M Buy
26,685
+1,611
+6% +$1.01M 0.08% 154
2022
Q2
$14.8M Sell
25,074
-256
-1% -$166K 0.06% 171
2022
Q1
$17.7M Sell
25,330
-747
-3% -$473K 0.06% 170
2021
Q4
$16.5M Buy
26,077
+2,046
+9% +$1.26M 0.06% 177
2021
Q3
$14.5M Buy
24,031
+156
+0.7% +$96.8K 0.06% 189
2021
Q2
$13.3M Buy
23,875
+1,292
+6% +$655K 0.05% 196
2021
Q1
$10.7M Buy
22,583
+3,049
+16% +$1.48M 0.05% 214
2020
Q4
$9.44M Buy
19,534
+1,277
+7% +$689K 0.04% 218
2020
Q3
$10.2M Buy
18,257
+2,892
+19% +$1.75M 0.05% 190
2020
Q2
$9.58M Buy
15,365
+1,054
+7% +$598K 0.06% 186
2020
Q1
$6.99M Buy
14,311
+24
+0.2% +$9.9K 0.05% 205
2019
Q4
$5.36M Buy
14,287
+737
+5% +$248K 0.03% 249
2019
Q3
$3.76M Sell
13,550
-164
-1% -$48.5K 0.02% 301
2019
Q2
$4.29M Buy
13,714
+369
+3% +$123K 0.03% 272
2019
Q1
$5.48M Sell
13,345
-83
-0.6% -$34.2K 0.03% 221
2018
Q4
$5.01M Buy
13,428
+272
+2% +$99.6K 0.04% 193
2018
Q3
$5.32M Buy
13,156
+266
+2% +$101K 0.03% 207
2018
Q2
$4.45M Buy
12,890
+605
+5% +$189K 0.03% 234
2018
Q1
$4.23M Sell
12,285
-33
-0.3% -$11.5K 0.03% 236
2017
Q4
$4.63M Buy
12,318
+634
+5% +$257K 0.03% 237
2017
Q3
$5.22M Buy
11,684
+264
+2% +$126K 0.03% 213
2017
Q2
$5.61M Buy
11,420
+422
+4% +$185K 0.04% 188
2017
Q1
$4.26M Buy
10,998
+293
+3% +$109K 0.03% 235
2016
Q4
$3.93M Sell
10,705
-78
-0.7% -$29.7K 0.03% 242
2016
Q3
$4.33M Sell
10,783
-605
-5% -$243K 0.03% 229
2016
Q2
$3.98M Buy
11,388
+175
+2% +$67.4K 0.03% 232
2016
Q1
$4.04M Buy
11,213
+302
+3% +$124K 0.03% 226
2015
Q4
$5.92M Sell
10,911
-394
-3% -$213K 0.05% 161
2015
Q3
$5.26M Buy
11,305
+122
+1% +$65.5K 0.04% 170
2015
Q2
$5.71M Buy
11,183
+276
+3% +$135K 0.04% 181
2015
Q1
$4.92M Buy
10,907
+568
+5% +$241K 0.03% 197
2014
Q4
$4.24M Sell
10,339
-2,352
-19% -$925K 0.03% 209
2014
Q3
$4.58M Sell
12,691
-207
-2% -$69.4K 0.03% 224
2014
Q2
$3.64M Sell
12,898
-414
-3% -$123K 0.02% 272
2014
Q1
$4M Buy
13,312
+547
+4% +$169K 0.02% 254
2013
Q4
$3.51M Buy
12,765
+81
+0.6% +$23.3K 0.02% 264
2013
Q3
$3.97M Buy
12,684
+107
+0.9% +$28.1K 0.03% 241
2013
Q2
$2.83M Buy
+12,577
New +$2.93M 0.02% 282

Other funds holding REGN

CIBC Asset Management's REGN Position: Q2 2026 in Review

CIBC Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2% in Q2 2026, selling an estimated $583K and leaving 41,660 shares worth $26M. The position accounts for 0.06% of the portfolio, ranked #226.

CIBC Asset Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $35.1M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • CIBC Asset Management held 41,660 shares of Regeneron Pharmaceuticals worth $26M as of Q2 2026.
  • CIBC Asset Management sold 857 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $583K.
  • Regeneron Pharmaceuticals made up 0.06% of CIBC Asset Management's portfolio in Q2 2026, its #226 holding.
  • CIBC Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • CIBC Asset Management's Regeneron Pharmaceuticals position peaked at $35.1M in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.